Diagnosing Preclinical and Prodromal Neurodegenerative Diseases—The Clinical Is Political

Claire M. Erickson,Emily A. Largent

DOI: https://doi.org/10.1001/jamaneurol.2023.5684

IF: 29.907

2024-02-19

JAMA Neurology

Abstract:This Viewpoint describes clinical and political considerations for individuals diagnosed with neurodegenerative conditions during the preclinical or prodromal stage.

clinical neurology

What problem does this paper attempt to address?

Preclinical Alzheimer Disease—Early Diagnosis or Overdiagnosis?

Kenneth M. Langa,James F. Burke

DOI: https://doi.org/10.1001/jamainternmed.2019.2629

2019-09-01

JAMA Internal Medicine

Abstract:This Viewpoint argues that the shift from treating patients with symptomatic Alzheimer disease to treating those with preclinical disease carries the risk of overdiagnosis.

medicine, general & internal
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Bruno Dubois,Harald Hampel,Howard H. Feldman,Philip Scheltens,Paul Aisen,Sandrine Andrieu,Hovagim Bakardjian,Habib Benali,Lars Bertram,Kaj Blennow,Karl Broich,Enrica Cavedo,Sebastian Crutch,Jean‐François Dartigues,Charles Duyckaerts,Stéphane Epelbaum,Giovanni B. Frisoni,Serge Gauthier,Remy Genthon,Alida A. Gouw,Marie‐Odile Habert,David M. Holtzman,Miia Kivipelto,Simone Lista,José‐Luis Molinuevo,Sid E. O'Bryant,Gil D. Rabinovici,Christopher Rowe,Stephen Salloway,Lon S. Schneider,Reisa Sperling,Marc Teichmann,Maria C. Carrillo,Jeffrey Cummings,Cliff R. Jack,2015; Washington DC Proceedings of the Meeting of the International Working Group and the American Alzheimer's Association on “The Preclinical State of AD”; July 23,

DOI: https://doi.org/10.1016/j.jalz.2016.02.002

2016-03-01

Abstract:During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021

A.P. Porsteinsson,R.S. Isaacson,S. Knox,M.N. Sabbagh,I. Rubino

DOI: https://doi.org/10.14283/jpad.2021.23

2021-01-01

Abstract:Alzheimer’s disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer’s disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impairment and then Alzheimer’s disease dementia. Recently, clinicians have been encouraged to diagnose Alzheimer’s earlier, before patients have progressed to Alzheimer’s disease dementia. The early and accurate detection of Alzheimer’s disease-associated symptoms and underlying disease pathology by clinicians is fundamental for the screening, diagnosis, and subsequent management of Alzheimer’s disease patients. It also enables patients and their caregivers to plan for the future and make appropriate lifestyle changes that could help maintain their quality of life for longer. Unfortunately, detecting early-stage Alzheimer’s disease in clinical practice can be challenging and is hindered by several barriers including constraints on clinicians’ time, difficulty accurately diagnosing Alzheimer’s pathology, and that patients and healthcare providers often dismiss symptoms as part of the normal aging process. As the prevalence of this disease continues to grow, the current model for Alzheimer’s disease diagnosis and patient management will need to evolve to integrate care across clinical disciplines and the disease continuum, beginning with primary care. This review summarizes the importance of establishing an early diagnosis of Alzheimer’s disease, related practical ‘how-to’ guidance and considerations, and tools that can be used by healthcare providers throughout the diagnostic journey.
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson's Disease: A Narrative Review

Eva Schaeffer,Rezzak Yilmaz,Erik K. St. Louis,Alastair J. Noyce

DOI: https://doi.org/10.3233/jpd-230428

2024-07-13

Journal of Parkinson s Disease

Abstract:The ability to identify individuals in the prodromal phase of Parkinson's disease has improved in recent years, raising the question of whether and how those affected should be informed about the risk of future disease. Several studies investigated prognostic counselling for individuals with isolated REM sleep behavior disorder and have shown that most patients want to receive information about prognosis, but autonomy and individual preferences must be respected. However, there are still many unanswered questions about risk disclosure or early diagnosis of PD, including the impact on personal circumstances, cultural preferences and specific challenges associated with different profiles of prodromal symptoms, genetic testing or biomarker assessments. This narrative review aims to summarize the current literature on prognostic counselling and risk disclosure in PD, as well as highlight future perspectives that may emerge with the development of new biomarkers and their anticipated impact on the definition of PD.

neurosciences
Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework

Lee E Neilson,Joseph F Quinn,Miranda M Lim

DOI: https://doi.org/10.14336/ad.2022.1024

2024-01-01

Aging and Disease

Abstract:As the prevalence of Parkinson's disease (PD) grows, so too does the population at-risk of developing PD, those in the so-called prodromal period. This period can span from those experiencing subtle motor deficits yet not meeting full diagnostic criteria or those with physiologic markers of disease alone. Several disease-modifying therapies have failed to show a neuroprotective effect. A common criticism is that neurodegeneration, even in the early motor stages, has advanced too far for neuro-restoration-based interventions to be effective. Therefore, identifying this early population is essential. Once identified, these patients could then potentially benefit from sweeping lifestyle modifications to alter their disease trajectory. Herein, we review the literature on risk factors for, and prodromal symptoms of, PD with an emphasis on ones which may be modifiable in the earliest possible stages. We propose a process for identifying this population and speculate on some strategies which may modulate disease trajectory. Ultimately, this proposal warrants prospective studies.

geriatrics & gerontology,gerontology
Ethical issues in early diagnosis and prevention of Alzheimer disease

Peter J Whitehouse

DOI: https://doi.org/10.31887/dcns.2019.21.1/pwhitehouse

2019-03-31

Dialogues in Clinical Neuroscience

Abstract:This paper considers ethical issues related to early diagnosis and all forms of prevention of Alzheimer disease and related conditions. It offers a critical view of the current state of scientific, clinical, and social responses to the growing number of older people with cognitive challenges, and suggests how priorities going forward should be different from those receiving most attention today. We begin with a review of global policy efforts, consider the fundamental goals of prevention, examine issues surrounding early diagnosis, explore more deeply values associated with efforts to prevent age associated cognitive decline, and conclude by considering often unexplored ethical issues that contextualize the field and should influence our approaches to the future.

neurosciences
Neurodegenerative Diseases: The Value of Early Predictive End Points

Sarah Janicki Hsieh,Zoi Alexopoulou,Nitin Mehrotra,Arie Struyk,S. Aubrey Stoch

DOI: https://doi.org/10.1002/cpt.2544

2022-03-02

Abstract:Use of early predictive biomarkers of neurodegenerative disease in phase I clinical trials may improve the translation of novel drug therapies from preclinical development through late-stage studies. This article provides a categorical summary of promising biomarker approaches or clinical end points in molecular, cellular, metabolic, electrophysiological, or clinical function that can be used to predict or quantify the progression of neurodegenerative disorders and guide program support.

pharmacology & pharmacy
Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review

Miren Altuna,Iñigo Ruiz,María Victoria Zelaya,Maite Mendioroz

DOI: https://doi.org/10.3390/medicina58040473

2022-03-25

Medicina

Abstract:Prion diseases are progressive and irreversible neurodegenerative disorders with a low incidence (1.5–2 cases per million per year). Genetic (10–15%), acquired (anecdotal) and sporadic (85%) forms of the disease have been described. The clinical spectrum of prion diseases is very varied, although the most common symptoms are rapidly progressive dementia, cerebellar ataxia and myoclonus. Mean life expectancy from the onset of symptoms is 6 months. There are currently diagnostic criteria based on clinical phenotype, as well as neuroimaging biomarkers (magnetic resonance imaging), neurophysiological tests (electroencephalogram and polysomnogram), and cerebrospinal fluid biomarkers (14-3-3 protein and real-time quaking-induced conversion (RT-QuIC)). The sensitivity and specificity of some of these tests (electroencephalogram and 14-3-3 protein) is under debate and the applicability of other tests, such as RT-QuIC, is not universal. However, the usefulness of these biomarkers beyond the most frequent prion disease, sporadic Creutzfeldt–Jakob disease, remains unclear. Therefore, research is being carried out on new, more efficient cerebrospinal fluid biomarkers (total tau, ratio total tau/phosphorylated tau and neurofilament light chain) and potential blood biomarkers (neurofilament light chain, among others) to try to universalize access to early diagnosis in the case of prion diseases.
Biomarkers for Managing Neurodegenerative Diseases

Lara Cheslow,Adam E. Snook,Scott A. Waldman

DOI: https://doi.org/10.3390/biom14040398

IF: 6.064

2024-03-27

Biomolecules

Abstract:Neurological disorders are the leading cause of cognitive and physical disability worldwide, affecting 15% of the global population. Due to the demographics of aging, the prevalence of neurological disorders, including neurodegenerative diseases, will double over the next two decades. Unfortunately, while available therapies provide symptomatic relief for cognitive and motor impairment, there is an urgent unmet need to develop disease-modifying therapies that slow the rate of pathological progression. In that context, biomarkers could identify at-risk and prodromal patients, monitor disease progression, track responses to therapy, and parse the causality of molecular events to identify novel targets for further clinical investigation. Thus, identifying biomarkers that discriminate between diseases and reflect specific stages of pathology would catalyze the discovery and development of therapeutic targets. This review will describe the prevalence, known mechanisms, ongoing or recently concluded therapeutic clinical trials, and biomarkers of three of the most prevalent neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD).

biochemistry & molecular biology
Detection and treatment of Alzheimer’s disease in its preclinical stage

Michael S. Rafii,Paul S. Aisen

DOI: https://doi.org/10.1038/s43587-023-00410-4

2023-05-18

Nature Aging

Abstract:Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer’s disease (AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of symptoms by decades. Treatment during the preclinical AD phase offers an optimal opportunity for slowing the progression of disease. However, trial design in this population is complex. In this Review, we discuss the recent advances in accurate plasma measurements, new recruitment approaches, sensitive cognitive instruments and self-reported outcomes that have facilitated the successful launch of multiple phase 3 trials for preclinical AD. The recent success of anti-amyloid immunotherapy trials in symptomatic AD has increased the enthusiasm for testing this strategy at the earliest feasible stage. We provide an outlook for standard screening of amyloid accumulation at the preclinical stage in clinically normal individuals, during which effective therapy to delay or prevent cognitive decline can be initiated.
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management

James E. Galvin,Paul Aisen,Jessica B. Langbaum,Eric Rodriguez,Marwan Sabbagh,Richard Stefanacci,Robert A. Stern,Elizabeth A. Vassey,Arno de Wilde,Neva West,Ivana Rubino

DOI: https://doi.org/10.3389/fneur.2020.592302

IF: 3.4

2021-01-22

Frontiers in Neurology

Abstract:Alzheimer's disease (AD) is a progressive, neurodegenerative disease that creates complex challenges and a significant burden for patients and caregivers. Although underlying pathological changes due to AD may be detected in research studies decades prior to symptom onset, many patients in the early stages of AD remain undiagnosed in clinical practice. Increasing evidence points to the importance of an early and accurate AD diagnosis to optimize outcomes for patients and their families, yet many barriers remain along the diagnostic journey. Through a series of international working group meetings, a diverse group of experts contributed their perspectives to create a blueprint for a patient-centered diagnostic journey for individuals in the early stages of AD and an evolving, transdisciplinary care team. Here, we discuss key learnings, implications, and recommendations.

neurosciences,clinical neurology
An early diagnosis is not the same as a timely diagnosis of Parkinson's disease

Richard Nathaniel Rees,Anita Prema Acharya,Anette Schrag,Alastair John Noyce

DOI: https://doi.org/10.12688/f1000research.14528.1

2018-07-18

F1000Research

Abstract:Parkinson’s disease is a common neurodegenerative condition that has significant costs to the individual patient and to society. The pathology starts up to a decade before symptoms are severe enough to allow a diagnosis using current criteria. Although the search for disease-modifying treatment continues, it is vital to understand what the right time is for diagnosis. Diagnosis of Parkinson’s disease is based on the classic clinical criteria, but the presence of other clinical features and disease biomarkers may allow earlier diagnosis, at least in a research setting. In this review, we identify the benefits of an early diagnosis, including before the classic clinical features occur. However, picking the right point for a “timely” diagnosis will vary depending on the preferences of the individual patient, efficacy (or existence) of disease-modifying treatment, and the ability for health systems to provide support and management for individuals at every stage of the disease. Good evidence for the quality-of-life benefits of existing symptomatic treatment supports the argument for earlier diagnosis at a time when symptoms are already present. This argument would be significantly bolstered by the development of disease-modifying treatments. Benefits of early diagnosis and treatment would affect not only the individual (and their families) but also the wider society and the research community. Ultimately, however, shared decision-making and the principles of autonomy, beneficence, and non-maleficence will need to be applied on an individual basis when considering a “timely” diagnosis.
Alzheimer's Disease - Perspective from Political Science: Public Policy Issues

Robert H Blank

DOI: https://doi.org/10.1177/1073110518804234

Abstract:The paper outlines the policy context and summarizes the numerous policy issues that AD raises from the more generic to the unique. It posits that strong public fears of AD and its future prevalence projections and costs, raise increasingly difficult policy dilemmas. After reviewing the costs in human lives and money and discussing the latest U.S. policy initiatives, the paper presents two policy areas as examples the demanding policy decisions we face. The first focuses on the basic regulatory function of protecting the public from those who would exploit these fears. The second centers on the well-debated issues of advance directives and euthanasia that surround AD. Although more dialogue, education and research funding are needed to best serve the interests of AD patients and families as well as society at large, this will be challenging because of the strong feelings and divisions AD engenders.
Relationship of Pathogeneses with Diagnostic and Therapeutic Approaches to Alzheimer’s Disease

KONG Yan-Yan,GUAN Yi-Hui,ZHENG Ping

DOI: https://doi.org/10.3969/j.issn.1008-0678.2012.04.018

2012-01-01

Abstract:Alzheimer’s disease(AD) is characterized by early neuropathological pathways-extracellular fibrillar β-amyloid(Aβ) deposits in the brain,intracellular neurofibrillary tangles(NFTs),possibly leading to synaptic dysfunction,neurodegeneration and cognitive/functional decline.The clinical diagnosis of probable AD based on standard diagnostic criteria does not take into account the long preclinical and prodromal course of AD.Diagnosis was based on structured history,neurological examination and neuropsychological assessment,with emphasis on qualitative as well as quantitative aspects of performance.AD-related pathophysiological changes can occur many years and even decades before the appearance of clinical dementia syndrome.Biomarkers that are related to the pathophysiology of AD may thus be helpful in detecting the preclinical stages of disease,and improve early and differential diagnosis,provided that the biomarkers were specific enough to avoid interfering with normal processes and accuracy of preclinical diagnosis of AD was increasingly important for therapeutic and prognostic investigations.
Ethical issues in Alzheimer's disease: an overview

Antoine Leuzy,Serge Gauthier

DOI: https://doi.org/10.1586/ern.12.38

Abstract:Alzheimer's disease (AD) accounts for the majority of dementia cases and leaves clinicians, patients, family members, caregivers, and researchers faced with numerous ethical issues that vary and evolve as a function of disease stage and severity. While the disclosure of a diagnosis of AD dementia is difficult enough, advances in the neurobiology of AD--embodied in the recent revisions to the AD diagnostic guidelines--have translated into an increasing shift toward the diagnosis being made in its pre-dementia stages, when patients have full insight into their prognosis. Genetic issues in AD are significant in the case of rare families with an early onset (before age 65) form of the disease, owing to the presence of deterministic mutations. While genetic testing for the apolipoprotein E (APOE) gene--a risk factor for sporadic AD--is widely debated, it may become necessary in the context of novel disease-modifying drugs. The current symptomatic drugs--cholinesterase inhibitors (CIs) and the NMDA receptor antagonist memantine--are relatively simple to use but their access is limited in many countries by economic considerations and therapeutic nihilism. Although their efficacy is modest, they influence the design of protocols for new drugs since placebo treatment in clinical trials involving patients with established dementia is rarely allowed beyond 3 months. Driving privileges are lost in the moderate stages of dementia, with this decision ideally reached using a standardized assessment algorithm. Physical restraints are still overused in moderate-to-severe stages, but the alternative non-pharmacological therapies and caregiver training programs are not yet fully validated using randomized studies. End-of-life care is slowly moving towards a palliative care approach similar to that for end-stage cancer. There will be new drugs in the near future, some of which will delay progression from prodromal stages to dementia, but their use will require careful stopping rules.
Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective

Johannes R. Streffer,Igor D. Grachev,Cheryl Fitzer‐Attas,Baltazar Gomez‐Mancilla,Babak Boroojerdi,Juliana Bronzova,Susanne Ostrowitzki,Stephen J. Victor,Paulo Fontoura,Robert Alexander,Cheryl Fitzer-Attas,Baltazar Gomez-Mancilla

DOI: https://doi.org/10.1002/mds.25017

IF: 9.698

2012-04-15

Movement Disorders

Abstract:Realizing that 60% to 80% of dopaminergic nigrostriatal neurons are nonfunctional at the time of clinical diagnosis, there is an emerging consensus that disease-modifying treatments should be initiated in the earliest stages of Parkinson's disease (PD). To date, clinical trial designs and metrics in PD have been focused on motor symptoms as the core feature of the clinical disease. To identify earlier or "pre-motor" populations in PD, new markers have been proposed. We address the prerequisites needed to use these pre-motor markers in clinical trials for the selection of subjects, definition of populations, and monitoring of disease progression. This may require the development of new diagnostic criteria potentially based on non-motor clinical signs, imaging techniques, or biological features, all requiring discussion in a regulatory framework. Questions addressed include: Which steps must be taken to gain a broad consensus in the field from academic opinion leaders, patient advocacy groups, regulatory bodies, and industry? How do we prevent the selection of subgroups, which may not be representative of the full disease spectrum? Is there a way forward in personalized medicine? How do we balance risk and benefit in an at-risk population? While many tools are available, a concerted effort is required to develop integrated data sets, as well as to achieve the necessary standardization for multicenter clinical trials. To this end, public-private consortia (including academic centers, patient advocacy groups, and industry) will be of crucial importance to prospectively investigate and define the best tools and treatment paradigms.

clinical neurology
The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

Filippo Baldacci,Sonia Mazzucchi,Alessandra Della Vecchia,Linda Giampietri,Nicola Giannini,Maya Koronyo-Hamaoui,Roberto Ceravolo,Gabriele Siciliano,Ubaldo Bonuccelli,Fanny M. Elahi,Andrea Vergallo,Simone Lista,Filippo Sean Giorgi,Harald Hampel

DOI: https://doi.org/10.1080/14737159.2020.1731306

2020-02-27

Expert Review of Molecular Diagnostics

Abstract:Introduction: The postmortem examination still represents the reference standard for detecting the pathological nature of chronic neurodegenerative diseases (NDD). This approach displays intrinsic conceptual limitations since NDD represent a dynamic spectrum of partially overlapping phenotypes, shared pathomechanistic alterations that often give rise to mixed pathologies.Areas covered: We scrutinized the international clinical diagnostic criteria of NDD and the literature to provide a roadmap toward a biomarker-based classification of the NDD spectrum. A few pathophysiological biomarkers have been established for NDD. These are time-consuming, invasive, and not suitable for preclinical detection. Candidate screening biomarkers are gaining momentum. Blood neurofilament light-chain represents a robust first-line tool to detect neurodegeneration tout court and serum progranulin helps detect genetic frontotemporal dementia. Ultrasensitive assays and retinal scans may identify Aβ pathology early, in blood and the eye, respectively. Ultrasound also represents a minimally invasive option to investigate the substantia nigra. Protein misfolding amplification assays may accurately detect α-synuclein in biofluids.Expert opinion: Data-driven strategies using quantitative rather than categorical variables may be more reliable for quantification of contributions from pathophysiological mechanisms and their spatial-temporal evolution. A systems biology approach is suitable to untangle the dynamics triggering loss of proteostasis, driving neurodegeneration and clinical evolution.

pathology
Pre‐diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases

Nol Swaddiwudhipong,David J. Whiteside,Frank H. Hezemans,Duncan Street,James B. Rowe,Timothy Rittman

DOI: https://doi.org/10.1002/alz.12802

2022-10-14

Abstract:Introduction The pathophysiological processes of neurodegenerative diseases begin years before diagnosis. However, pre‐diagnostic changes in cognition and physical function are poorly understood, especially in sporadic neurodegenerative disease. Methods UK Biobank data were extracted. Cognitive and functional measures in individuals who subsequently developed Alzheimer's disease (AD), Parkinson disease, frontotemporal dementia, progressive supranuclear palsy, dementia with Lewy bodies, or multiple system atrophy were compared against individuals without neurodegenerative diagnoses. The same measures were regressed against time to diagnosis, after adjusting for the effects of age. Results There was evidence for pre‐diagnostic cognitive impairment and decline with time, particularly in AD. Pre‐diagnostic functional impairment and decline were observed in multiple diseases. Discussion The scale and longitudinal follow‐up of UK Biobank participants provides evidence for cognitive and functional decline years before symptoms become obvious in multiple neurodegenerative diseases. Identifying pre‐diagnostic functional and cognitive changes could improve selection for preventive and early disease‐modifying treatment trials.
A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials

Anthony E. Lang

DOI: https://doi.org/10.1002/mds.23609

IF: 9.698

2011-04-01

Movement Disorders

Abstract:The neurodegenerative process is well established in Parkinson patients presenting to a physician with early motor signs. There is increasing evidence that a variety of nonmotor features can antedate the typical presentation by many years. As the search for successful disease-modifying treatment advances, it is logical to consider how this could be applied to patients in the earliest stages of the disease, indeed before motor features develop, with the obvious goal of delaying and even preventing the onset of the motor syndrome. However, many of these nonmotor symptoms are rather nonspecific and are not uncommon in the general population. Being able to identify individuals in whom these features are more likely to represent true premotor Parkinson's disease represents a major challenge. Until widely applicable and reliable biomarkers for the presence of Parkinson's disease-related pathology are developed (including biomarkers of disease severity and rate of progression), further evaluation of possible premotor features in selected populations will probably serve as the basis for future studies of disease-modifying therapies. This article will review the current status of premotor symptoms of Parkinson's disease and discuss their potential for early diagnosis and the design of neuroprotective trials.

clinical neurology
Challenges and Prospects in Advancing Clinical Neuropsychology

Julie Anne Péron

DOI: https://doi.org/10.1016/j.cortex.2024.08.001

IF: 4.644

2024-08-21

Cortex

Abstract:In the ever-evolving field of clinical neuropsychology, significant methodological and conceptual limitations hinder progress. To ensure the continued relevance of this discipline amidst remarkable advancements in neuroscience, medicine, and methodology, these obstacles must be addressed. This opinion article identifies inherent limitations within current clinical neuropsychology, including issues such as multi-collinearity in neuropsychological assessments, lack of validated tools reflecting contemporary cognitive function models, and the use of divergent theoretical frameworks in evaluations, leading to a gap between theory and practice. The disconnect between behavior and biomarkers, particularly evident in neurodegenerative diseases but also relevant for other pathologies, together with the rise of genetic analyses, necessitate change. Methodological improvements are crucial for ensuring the discipline's future relevance. Looking ahead, key perspectives and challenges are outlined, emphasizing the need for a holistic approach to cognitive functioning and congruent tools, patient engagement in experimental studies, rectification of biases, and exploration of variables like artificial intelligence and personality. Training professionals to bridge the gap between practice and research is essential. By addressing these challenges, clinical neuropsychology can not only adapt to the evolving landscape but also shape it, ensuring a brighter future for the field.

behavioral sciences,psychology, experimental,neurosciences

Diagnosing Preclinical and Prodromal Neurodegenerative Diseases—The Clinical Is Political

Preclinical Alzheimer Disease—Early Diagnosis or Overdiagnosis?

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021

Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson's Disease: A Narrative Review

Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework

Ethical issues in early diagnosis and prevention of Alzheimer disease

Neurodegenerative Diseases: The Value of Early Predictive End Points

Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review

Biomarkers for Managing Neurodegenerative Diseases

Detection and treatment of Alzheimer’s disease in its preclinical stage

Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management

An early diagnosis is not the same as a timely diagnosis of Parkinson's disease

Alzheimer's Disease - Perspective from Political Science: Public Policy Issues

Relationship of Pathogeneses with Diagnostic and Therapeutic Approaches to Alzheimer’s Disease

Ethical issues in Alzheimer's disease: an overview

Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective

The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

Pre‐diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases

A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials

Challenges and Prospects in Advancing Clinical Neuropsychology